Core Viewpoint - The article emphasizes the increased cardiovascular risks during summer due to high temperatures and suggests various protective measures for heart health. Group 1: Summer Heart Risks - Cardiovascular disease-related mortality increases by 2.1% for every 1°C rise in temperature [1] - Heart attack cases surge during summer, particularly after the hottest days, due to three main pressures: temperature extremes, cold food consumption, and emotional stress [1][2][3] Group 2: Recommendations to Avoid Heart Risks - Avoid drinking ice water immediately after exercise to prevent sudden blood vessel constriction and increased blood pressure [4] - Do not blow air conditioning directly on oneself after sweating; allow the body to adjust gradually [5] - Wait 10-15 minutes after sweating before taking a cold shower to prevent blood vessel spasms [6] - Limit sugary drinks; consuming more than two servings daily increases cardiovascular disease risk by approximately 21% [7] Group 3: Heart Health Practices - Drink warm water before bed and upon waking to dilute blood and reduce clotting risk [9] - Drink small amounts of water frequently rather than large quantities at once to avoid overloading the heart [10] - Incorporate fresh fruits and vegetables into the diet to ensure adequate potassium intake and support heart health [11] - Take short naps during the day to alleviate fatigue and support heart health [12] - Engage in brisk walking for at least 30 minutes daily to lower the risk of heart disease and stroke [13]

Kiniksa Pharmaceuticals International (KNSA) FY Conference June 10, 2025 08:00 AM ET Speaker0 Thank you. Good morning, everyone. I'm Paul Choi. I'm a biotech analyst here at Goldman Sachs. It's my pleasure to welcome Conixa for our session this morning on the day of the conference. I'm required to read off certain disclosures, which primarily relate to investment banking relationships that Goldman Sachs may have with firm, companies presenting here at the conference. These relationships include, investment ...

Core Insights - AMT Medical has developed the ELANA seamless heart bypass technology, allowing surgeries without chest opening, thus reducing patient trauma and recovery time [1][4][16] Industry Overview - Cardiovascular diseases (CVDs) remain a leading cause of death globally, with approximately 18.5 million deaths in 2023, projected to rise to 24 million by 2030 [2] - Traditional coronary artery bypass grafting (CABG) surgeries face significant challenges, including chest trauma, recovery difficulties, and high medical costs [2][3] Technology Advantages - The ELANA system utilizes laser-assisted vascular connections and specialized clips, enabling surgeries without sutures and heart-lung machines, thus maintaining blood circulation during procedures [4][5][7] - The system significantly reduces stroke risk from 3%-5% in traditional surgeries to less than 1% with ELANA, and lowers anastomosis leak rates from 8%-12% to below 2% [9][10] Market Potential - The global minimally invasive surgery market is projected to grow from $62 billion in 2023 to $130 billion by 2030, with cardiovascular devices accounting for over 30% of this market [3] - AMT's technology is adaptable for various surgical methods and has potential applications in peripheral vascular bypass and heart valve repair, expanding its market reach [10][15] Financial Backing - AMT has raised a total of €24.5 million (approximately $26 million) in funding, including a recent €22 million Series B round to accelerate CE certification and clinical trials in the U.S. [11][12][13] Future Plans - The company aims to achieve CE certification by 2026 and initiate FDA approval processes in 2027, targeting to reduce surgical costs by an additional 30% and benefit one million patients annually [15][16]

Core Points - The high incidence and mortality rates of cardiovascular diseases remain a significant public health challenge, prompting the launch of the 2025 People's Good Doctor Cardiovascular Health Science Popularization Action in Shanghai [1] - The initiative aims to enhance public health literacy and advance the prevention and treatment of cardiovascular diseases through scientific education [1] - A committee of experts from various prestigious medical institutions will guide the development of a precise and scientific cardiovascular health knowledge system [4] Group 1 - The 2025 People's Good Doctor Cardiovascular Health Science Popularization Action is supported by the Kunming Pharmaceutical Group and aims to cover over a thousand medical institutions nationwide [4] - The initiative emphasizes the importance of medical professionals in translating complex medical knowledge into accessible language for the public [1] - The action encourages active participation from the public to strengthen personal health responsibility [1] Group 2 - A committee of leading experts in cardiology has been formed to oversee the evaluation and guidance of science popularization works [4] - The initiative seeks to create opportunities for health education during medical consultations, integrating health knowledge dissemination into routine medical practice [1] - The goal is to ensure that health knowledge reaches every household, making it relevant to different demographics [1]

【环球网财经报道 马牧野】2025年5月21至23日，NHNE中国国际健康营养博览会在广州举行。本届展会汇集了全球超过1200家相关企业参展，吸引专业观 众到场累计超过10万人次。在诚志生命科技有限公司的展区内，一盒盒印有"力搏士®D-核糖冲剂"的产品吸引了与会展商与观众的目光，该产品不仅是国内 首款获批的以D-核糖为主要功效成分的、具有抗疲劳和耐缺氧双功能的保健食品，更是凭借其改善心肌能量代谢紊乱的卓越功效，在心脏保护领域，正悄 然掀起一场静默的重大变革。 作为该款产品背后的推动者，诚志生命科技有限公司董事长高润香在会议同期举行的第十五届"特殊营养食品及特殊膳食"论坛上，以《D-核糖：助力心血管 慢病管理的临床新策略》为题，用详实的数据、完备的科研逻辑和产业实践案例，向业界传递了一个重要信号：D-核糖，可能正在改写人类对抗心血管疾 病的传统路径。 从实验室到临床，从运动场到病床，D-核糖的故事正在突破传统健康产业的边界，而高润香与她的团队，正致力于用科学和商业的双重力量，推动这场变 革的发生。本届NHNE中国国际健康营养博览会期间，环球网就D-核糖的发展过往和未来，对高润香进行了独家专访。 科学信仰：以效果 ...

中新网昆明5月9日电 (陈静 陆希成)9日，记者从云南省第一人民医院了解到，该院心脏大血管外科 近日成功为一位67岁的瓷化血管高危冠心病患者田先生(化名)实施"非体外循环心脏搭桥+血管吻合黑科 技"创新手术。目前，该患者术后恢复良好。"手术前我连床都下不了，现在能连续行走十多分钟，这感 觉像重获新生。"田先生接受采访时表示。 手术成功只是康复的第一步。记者在病房见到田先生时，他正在进行康复训练。"术后康复对此类 患者至关重要，甚至比手术本身更关键。"曹宇说，医院为田先生制定了个性化的三阶段康复计划，从 早期活动到心肺功能恢复，再到生活方式重塑。 医院康复团队告诉记者，田先生从术后最初只能床边坐5分钟，到现在能连续行走10多分钟，进步 显著。同时，营养师为其制定了心脏健康饮食方案，心理医生帮助他应对戒烟过程中的焦虑，形成全方 位康复体系。 田先生10余年来高血压控制不佳，最高血压达190/100mmHg，加上40年每天一包烟的习惯，导致 其心脏三支主要血管严重堵塞，主动脉全程高度钙化。医学上称这种情况为瓷化血管，意指血管变得像 瓷器一样僵硬脆弱，随时可能破裂。田先生同时还合并严重呼吸功能不全，氧分压仅为46.4 ...

带状疱疹多发于50岁以上的人群，患有糖尿病、慢性肾病、慢阻肺等慢性疾病患者以及患有系统性红斑 狼疮、类风湿关节炎等自身免疫疾病患者，患带状疱疹的风险也会比一般人高。 据统计，中国人水痘-带状疱疹病毒的感染率为90%，其中有30%的人在一生当中某个时候会患上带状疱 疹。 近日，多项研究揭示了关于带状疱疹疫苗接种的额外好处。 5月6日，《欧洲心脏杂志》（EHJ）最新发表来自韩国团队研究显示，接种带状疱疹疫苗还可能成为心 血管疾病的"意外克星"。 来自韩国庆熙大学医学院等机构的科学家针对220万名50岁以上人群进行的一项大规模研究发现，接种 带状疱疹疫苗的人群心血管事件（如中风、心力衰竭和冠心病）的风险降低了23%。 研究进一步分析显示，接种疫苗后2至3年内对心血管保护作用最为显著，且这种保护效应可持续长达8 年。研究还显示，男性、年龄小于60岁者获益更为明显。 带状疱疹是由水痘-带状疱疹病毒（VZV）引起的一种疾病。曾经患过水痘或者隐性感染过水痘-带状疱 疹病毒的人，在他们的余生中都携带着这种病毒。病毒隐藏在神经中，当免疫系统因疾病或年龄增长而 衰弱时，就会发展为带状疱疹。带状疱疹不仅会导致剧烈疼痛的皮疹，还可能 ...

Core Viewpoint - Chengyi Pharmaceutical (603811) has received approval from the National Medical Products Administration for the marketing application of the active pharmaceutical ingredient, Dobutamine Hydrochloride, which is used in the treatment of cardiovascular diseases [1] Group 1: Product Approval - The approved active pharmaceutical ingredient is a β-adrenergic agonist that stimulates cardiac β1 receptors, enhancing myocardial contractility while dilating peripheral blood vessels and reducing cardiac load [1] - Current domestic manufacturers include Zhejiang Ruixin Pharmaceutical and Shanghai Ziyuan Pharmaceutical [1] Group 2: R&D Investment - The company has invested approximately 5.1982 million yuan in the research and development of this active pharmaceutical ingredient [1] Group 3: Business Impact - The approval will enrich the company's product line and help expand its business scope, although it is not expected to have a significant impact on current performance [1]

撰文丨王聪 编辑丨王多鱼 排版丨水成文 心血管疾病 （CVD） 是全球头号致死病因。大多数临床和公共卫生指南传统上都是基于结构化运动的心脏 保护特性而制定的。例如，世界卫生组织 （WHO） 2020 年发布的《身体活动和久坐行为指南》中的大部 分证据都源自于主要记录休闲时间运动的自我报告测量。 对于许多成年人来说，定期进行结构化 （休闲时间） 运动可能缺乏吸引力或难以实现，参与率通常也很 低。而基于运动的心脏康复计划的退出率往往极高。作为日常生活一部分的非运动活动 （例如交通出行、 工作、家务或其他家庭活动） 所构成的 偶然身体活动 （IPA） ，可能在心血管疾病的一级和二级预防方面 具有可行性优势，因为它克服了结构化运动的若干障碍：即缺乏时间与动力、费用高昂、难以获取设施以 及对自身运动能力或技能缺乏信心。 近日，悉尼大学的研究人员在 Circulation 期刊发表了题为： Dose Response of Incidental Physical Activity Against Cardiovascular Events and Mortality 的研究论文。 该研究表明，对于老年人来说，每天只需进行 ...

合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 暂定议程名额有限 报名：首届全球心血管大会 | 奖项申报 报名：首届全球骨科大会 | 奖项评选 近日，Cardiac Dimensions 宣布完成了 5300 万美元 （合约 3.83亿人民币 ）的 超额认购 E 轮融资， Ally Bridge Group（汇桥资本） 领投，新投资者 Claret Capital Partners 参与，现有投资者也提供了重要支持。 该公司设计了 Carillon 系统，旨在在不损伤二尖瓣瓣叶的情况下恢复自然的二尖瓣功能。 公司计划利用这笔资金完成 Carillon 系统在美国的关键性研究， 并支持该系统的商业化。 # C a r i l l o n 二 尖瓣 轮廓 系统 研发背景 FMR病理机制： 心衰患者左心扩张导致二尖瓣前后叶闭合不全，血液通过二尖瓣反流或渗漏，进而减少心脏输送到身体其他部位的含氧血液量，损害心脏功 能，使心衰恶化。有数据显示，高达74%的心衰患者患有FMR，这是一个亟待解决的临床问题。 治疗现状： 经导管二尖瓣缘对缘修复术（M-TEER）2013年和2019年先后获FDA批准用于 ...